Relay Therapeutics (RLAY) Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. KBH
3. FDX
4. HONA
5. HTZ
6. HON
7. TTWO
8. HELP
9. GDYN
10. NKE

Go back to Relay Therapeutics (RLAY) Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

September 9, 2024 6:55 AM EDT

9.2-month median PFS in heavily pre-treated patients with PI3K-mutated, HR+/HER2- metastatic breast cancer at RP2D

33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D

Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia

Data support planned initiation of 2L pivotal study in 2025

Triplet combination with ribociclib expected to move into dose expansion in 1H 2025 & triplet combination with... More